Drug
RGT-419B
RGT-419B is a pharmaceutical drug with 2 clinical trials. Currently 2 active trials ongoing.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(100%)
Phase Distribution
Ph phase_1
2
100%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
2
all time
Status Distribution
Active(2)
Detailed Status
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
active_not_recruiting150%
recruiting150%
Recent Activity
2 active trials
Showing 2 of 2
recruitingphase_1
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT05304962
active_not_recruitingphase_1
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
NCT06299124
Clinical Trials (2)
Showing 2 of 2 trials
NCT05304962Phase 1
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT06299124Phase 1
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2